Literature DB >> 14667991

Progesterone antagonists and progesterone receptor modulators: an overview.

Irving M Spitz1.   

Abstract

Since the original description of the structure of the antiprogestin, mifepristone, was published, numerous related compounds have been synthesized which may function as progesterone antagonists (PAs) or progesterone receptor modulators (PRMs). The latter are mixed agonists-antagonists. Both PAs and PRMs have therapeutic applications in female health care. Mifepristone is predominantly a PA and displays only minimum agonist activity in certain systems. Together with a prostaglandin, mifepristone can terminate pregnancies of less than 9 weeks duration, and it may also be used at later gestational ages. Mifepristone causes expulsion of the uterine contents following intrauterine fetal death. A mifepristone-prostaglandin combination has been shown to be very effective treatment in women with menses delay of 11 days or less. Many PAs and PRMs display antiproliferative effects in the endometrium. Serum estradiol levels however remain in the early to mid-follicular phase range. For this reason, they have application in the treatment of endometriosis and myoma without being associated with bone loss and hypoestrogenism. PRMs may also find application in the treatment of dysfunctional bleeding as well as an adjunct to estrogens in hormone replacement therapy in postmenopausal women. Many PAs have contraceptive potential by suppressing follicular development and blocking the LH surge. Low doses may also be potential contraceptives by retarding endometrial maturation without affecting ovulation or inducing bleeding. Mifepristone is an excellent agent for use as an emergency "postcoital" contraceptive. PAs may also be useful in IVF programs to prevent a premature LH surge and to delay the emergence of the implantation window. In addition to their use in women's health care, mifepristone and several other PAs are potent antiglucocorticoid agents and may be used to treat ACTH-independent Cushing's syndrome. They may also be used in the treatment of tumors containing steroid receptors and in other situations which require suppression of the ACTH-cortisol axis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14667991     DOI: 10.1016/j.steroids.2003.08.007

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  20 in total

1.  X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids.

Authors:  Scott J Lusher; Hans C A Raaijmakers; Diep Vu-Pham; Bert Kazemier; Rolien Bosch; Ross McGuire; Rita Azevedo; Hans Hamersma; Koen Dechering; Arthur Oubrie; Marcel van Duin; Jacob de Vlieg
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

Review 2.  Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus.

Authors:  Margeaux Wetendorf; Francesco J DeMayo
Journal:  Int J Dev Biol       Date:  2014       Impact factor: 2.203

3.  Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators.

Authors:  Scott J Lusher; Hans C A Raaijmakers; Diep Vu-Pham; Koen Dechering; Tsang Wai Lam; Angus R Brown; Niall M Hamilton; Olaf Nimz; Rolien Bosch; Ross McGuire; Arthur Oubrie; Jacob de Vlieg
Journal:  J Biol Chem       Date:  2011-08-17       Impact factor: 5.157

4.  Molecular screening of Chinese medicinal plants for progestogenic and anti-progestogenic activity.

Authors:  H M Manir Ahmed; Jan-Ying Yeh; Yi-Chia Tang; Winston Teng-Kuei Cheng; Bor-Rung Ou
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

5.  Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study.

Authors:  Lynnette K Nieman; Wendy Blocker; Tonja Nansel; Sheila Mahoney; James Reynolds; Diana Blithe; Robert Wesley; Alicia Armstrong
Journal:  Fertil Steril       Date:  2010-11-05       Impact factor: 7.329

6.  In silico assessment of new progesterone receptor inhibitors using molecular dynamics: a new insight into breast cancer treatment.

Authors:  Vahid Zarezade; Marzie Abolghasemi; Fakher Rahim; Ali Veisi; Mohammad Behbahani
Journal:  J Mol Model       Date:  2018-11-10       Impact factor: 1.810

7.  Sex differences in cell proliferation and glucocorticoid responsiveness in the zebra finch brain.

Authors:  Amnon Katz; Anahid Mirzatoni; Yin Zhen; Barney A Schlinger
Journal:  Eur J Neurosci       Date:  2008-07       Impact factor: 3.386

8.  Estradiol and progesterone-induced slowing of gonadotropin-releasing hormone pulse frequency is not reversed by subsequent administration of mifepristone.

Authors:  Christopher R McCartney; Susan K Blank; John C Marshall
Journal:  Endocrine       Date:  2009-07-16       Impact factor: 3.633

9.  The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells.

Authors:  Xia Luo; Ping Yin; John S Coon V; You-Hong Cheng; Ronald D Wiehle; Serdar E Bulun
Journal:  Fertil Steril       Date:  2010-01-08       Impact factor: 7.329

10.  Progesterone effects on cell growth of U373 and D54 human astrocytoma cell lines.

Authors:  Gabriela González-Agüero; Andrés A Gutiérrez; Diana González-Espinosa; José D Solano; Rocío Morales; Aliesha González-Arenas; Edith Cabrera-Muñoz; Ignacio Camacho-Arroyo
Journal:  Endocrine       Date:  2007-11-15       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.